Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening.

ABSTRACT:

Background and aims

Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing.

Methods

Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, hi

SUBMITTER: Abedellatif SE 

PROVIDER: S-EPMC11360789 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature